SCHEMBL3016152

SCHEMBL3016152

O=[N+]([O-])c1cc(S(=O)(=O)N2CCN(c3nc(-c4cc(F)cc(F)c4)cs3)CC2)ccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.60
ALDH1A1 P00352 3/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MAPT P10636 6/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
VCAM1 P19320 3/20 0.52
NPBWR1 P48145 1/20 0.51
MCHR1 Q99705 1/20 0.51
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 2/20 0.48
POLB P06746 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MITF O75030 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645434 0.96 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3001243 0.95 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3653812 0.91 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3013968 0.90 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3012820 0.90 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3003816 0.89 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3001212 0.89 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3018885 0.89 VCAM1 (0.54) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3011715 0.89 MEN1 (0.57) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3001871 0.89 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.